Clinical Trials

Inclusion Criteria:

1. Patient is ≥ 40 years-old.
2. If female, patient is post-menopausal or negative pregnancy (blood or urine) test through Mayo laboratory prior to nuclear imaging study.

AL-CM Arm:

1. Patient has documented AL-CM defined as:
   1. Presence of amyloid in cardiac biopsy tissue (as determined by congo red stain or sulfated alcin blue stain), or
   2. Evidence of cardiac amyloid involvement by echocardiography and presence of amyloid in non-cardiac biopsy tissue
   3. High clinical suspicion of AL amyloid and subtyping by mass spectrometry ordered for confirmation

ATTR-CM Arm:

1. Variant TTR amyloid cardiomyopathy as defined as:
   1. Known amyloid-associated genotype by direct sequencing of entire TTR gene and presence of amyloid in cardiac biopsy tissue (as determined by congo red stain, alcin blue stain, or mass spec analysis), or
2. Variant TTR amyloid cardiomyopathy as defined as:
   1. Known amyloid-associated genotype by direct sequencing of entire TTR gene, evidence of cardiac involvement by echocardiography with left ventricle wall thickness > 12 mm and presence of amyloid in non-cardiac biopsy tissue (as determined by congo red stain, alcin blue stain, or mass spec analysis), or
3. Wild-type TTR amyloid cardiomyopathy as defined as:
   1. Normal TTR genotype and presence of TTR amyloid deposits in cardiac biopsy tissue (as determined by congo red stain and mass spec analysis), or
4. Wild-type TTR amyloid cardiomyopathy as defined as:
   1. Normal TTR genotype, evidence of cardiac involvement by echocardiography with left ventricle wall thickness > 12 mm and presence of TTR amyloid deposits in non-cardiac biopsy tissue (as determined by congo red stain and mass spec analysis).

Non-amyloid Control Arm:

1. No clinical or laboratory evidence of amyloid.